- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Neoadjuvant Nivolumab/Ipilimumab Improves RFS in Stage III Macroscopic Melanoma
June 24th 2020, 7:51pm
The neoadjuvant combination of nivolumab and ipilimumab continues to demonstrate a benefit in RFS compared with the combination given in the adjuvant setting in patients with stage III macroscopic melanoma.
Dr. Figel on Preclinical Research With Survivin Isoforms in Cancer Cells
June 24th 2020, 6:08pm
Sheila Figel, PhD, a neuro-oncologic scientist with Roswell Park Comprehensive Cancer Center, discusses preclinical research with canonical and noncanonical that are displayed on the surface of cancer cells.
Nivolumab/Ipilimumab Demonstrates OS Benefit in Advanced NSCLC With Brain Metastases
June 24th 2020, 1:00am
The combination of nivolumab and ipilimumab provided similar clinical benefit to that of chemotherapy when given as a frontline treatment for patients with advanced non–small cell lung cancer who had stable and treated brain metastases at baseline.
Tiragolumab/Atezolizumab Shows Early First-in-Human Efficacy in Frontline PD-L1+ NSCLC
June 24th 2020, 12:34am
Tiragolumab in combination with atezolizumab (Tecentriq) demonstrated early clinical activity and was found to be well tolerated in patients with advanced solid tumors, including those with metastatic non–small cell lung cancer who were PD-L1 positive and had not received prior checkpoint inhibition.
Dr. Horn on Updated IMpower133 Data in Small Cell Lung Cancer
June 23rd 2020, 11:37pm
Leora Horn, MD, MSc, discusses data from an updated analysis of the phase 3 IMpower133 trial, which examined the first-line combination of atezolizumab (Tecentriq), carboplatin, and etoposide in small cell lung cancer.
Tucatinib Produces Potent Preclinical Antitumor Activity, CNS Penetrance in HER2+ Breast Cancer
June 23rd 2020, 11:21pm
The HER2-selective TKI tucatinib (Tukysa) demonstrated potent antitumor activity alone and in combination with ado-trastuzumab emtansine (T-DM1; Kadcyla) in HER2-overexpressing breast cancer cell lines and xenograft models.
SM-88 Shows Promising Preclinical Antitumor Activity Across Several Cancers
June 23rd 2020, 11:15pm
The oral modified dysfunctional tyrosine SM-88 has demonstrated antitumor activity and appears to broadly effect the immune dynamics of the tumor microenvironment, according to early data from 2 xenograft studies.
Utility of Minimally Invasive Plasma-Based NGS Expands in NSCLC
June 23rd 2020, 8:21pm
Plasma-based next-generation sequencing continues to offer a minimally invasive, highly specific modality to identify patients with actionable alterations in non–small cell lung cancer.
ctDNA Clearance Shows Correlation With PFS Improvement in EGFR+/MET+ NSCLC
June 23rd 2020, 7:47pm
Circulating tumor DNA clearance of EGFR mutation may be predictive of prolonged progression-free survival for patients with EGFR-mutant, MET-amplified non–small cell lung cancer with detectable ctDNA at baseline.
Assessing the Actionability of KRAS Mutations in NSCLC
June 23rd 2020, 6:45pm
KRAS mutations are found in approximately in 25% of all NSCLC, and it was not until recently that the previously coined “undruggable target” showed signals of actionability with KRAS mutation–specific therapy, tumor-suppressor–specific therapy, and anti-inflammatory therapy.
Dr. Wang on Challenges With Checkpoint Inhibitors in CRC
June 23rd 2020, 6:20pm
Timothy Cragin Wang, MD, discusses the lack of response to checkpoint inhibitors in colorectal cancer.
COVID-19 Pandemic Accelerates RWD-Based Initiatives in Oncology
June 23rd 2020, 4:41pm
The FDA is presently spearheading several initiatives in light of COVID-19 aimed at refining the role of RWD in cancer care to guide clinical trial development, procure answers to pressing clinical questions, and support regulatory decisions for in vitro diagnostics.
Enfortumab Vedotin Demonstrates Additional Mechanisms of Action in UC Models
June 23rd 2020, 4:13pm
In urothelial carcinoma models, enfortumab vedotin-ejfv appeared to promote multiple mechanisms of action such as bystander cell killing, supporting the use of the agent either alone or in combination with pembrolizumab.
Dr. Galsky on Sequencing Questions in Urothelial Cancer
June 23rd 2020, 2:40pm
Matthew Galsky, MD, discusses sequencing questions in urothelial carcinoma.
Suggested Benefit of Novel BTK Inhibitor Observed in MCL Models and in NHL Combo Regimen
June 23rd 2020, 2:17pm
In preclinical models, the novel irreversible BTK inhibitor TG-1701 demonstrated similar activity to ibrutinib in mantle cell lymphoma cell lines and showed additive benefit when combined with ublituximab and umbralisib in non-Hodgkin lymphoma model.
Dr. Shore on Immunotherapy Targeting PSA and PSMA in Biochemically Recurrent Prostate Cancer
June 22nd 2020, 10:00pm
Neal D. Shore, MD, FACS, discusses immunotherapy targeting prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) in biochemically recurrent prostate cancer.
Atezolizumab Regimen Improves OS in Frontline Extensive-Stage Small Cell Lung Cancer, Regardless of Biomarker Status
June 22nd 2020, 9:26pm
The combination of atezolizumab plus carboplatin/etoposide continued to demonstrate an improvement in overall survival versus chemotherapy alone as a frontline treatment for patients with extensive-stage small cell lung cancer.
Tucatinib Demonstrates Potent Activity in HER2-Mutant Tumor Models
June 22nd 2020, 9:05pm
Tucatinib was found to be a potent inhibitor of HER2-mutant signaling in vitro.
Dr. Rintoul on the Importance of MRD Assessment in NSCLC
June 22nd 2020, 9:00pm
Robert Rintoul, BSc, MB ChB, PhD, FRCP, discusses the importance of minimal residual disease assessment in patients with non–small cell lung cancer.
Survivin Isoforms Detection Predicts a Potential Role in Tumor Biology
June 22nd 2020, 6:09pm
Three main survivin isoforms demonstrated the ability to translocate to the surface of plasma membrane in multiple cell types, suggesting a targetable role as a molecular biomarker.